since 30 years Bannert Manlik


Helping you to realise your objectives

From start to successful completion


Klaus Manlik

Klaus Manlik

Managing Partner

More than 30 years experience in the pharmaceutical Industry

Ulrike Däxl

Ulrike Däxl

Managing Director Operations

Industry experience as a senior analyst for stock-listed pharmaceutical companies

Niek Stander

Niek Stander

Chief Commercial Officer

Experienced in pharmaceutical commercial, general management and financial leadership

Mathias Käsebier

Mathias Käsebier

Senior Director

Former executive of Boehringer Ingelheim – specialty in global OTC business and global nutritional supplements

Our people:

All our consultants come from the pharmaceutical industry or have had contact with the pharmaceutical industry. They have different focuses in their expertise:

A. Classic pharmaceutical sector with RX products and hospital sector
B. OTC and prescription-free sector
C. Finance 

It is our goal to be able to provide and realize our M&A services for our clients in a more individual and result-oriented manner in the future.

In addition to the pure brokerage activities, our clients appreciate and use our strategic consulting competence, especially medium-sized companies, when it comes to buying and selling companies and product portfolios.

Our global reach:

In addition to the home market Europe, one of our main focuses is Latin and South America and Emerging Markets. 

Asia, especially Japan, Korea and Southeast Asia are other core areas of Bannert Manlik.

By means of our own global database, we are able to optimally narrow down search profiles of clients to create the basis for a structured, targeted, successful search within a short period of time. 

In addition to various data bases (IMS, research databases, etc.), our database in particular contains personal information about the individual companies, financial details, portfolio details, development pipeline, succession planning and much more. 


We are strong in Europe, Latin America and Emerging Markets and have an extensive global network

Proprietary Global Database

BANNERT MANLIK’s unique proprietary global database includes more than 22.000 companies and more than 50.000 individuals with public as well as non-public information:

  • Rx companies
  • OTC companies
  • Generic companies
  • Nutraceutical companies
  • Phyto companies
  • Biotech companies
  • CMO’s
  • CRO‘s
  • Private Equity
  • …and more


Our Service Partner Network

We would like to offer our clients one-stop services. That is why we have built up a service partner network which completes our M&A Advisory Activities: We have access to professional market research institutes, marketing and sales agencies, interim management providers, contract research and regulatory affairs providers, contract producers and financial service providers. We can also offer recruiting services to our clients. 

Flexible outsourcing and payroll services

Recruitment of specialised roles

(GM, Sales/KAM, Medical, Market access etc.)

Interim management provider

Banking relationships

Management of European Marketing

Authorisations and patent advice

Contract research and regulatory affairs

Contract manufacters

Market research

Why Bannert Manlik?

There are many reasons why our clients rely on Bannert MANLIK’s 30 years of experience:

A. Our own global data base as well as the personal network of our consultants, which has matured over many years and is constantly renewed and improved.

B. We are a multi-national team. Our clients, who work on global projects, appreciate our geographical know-how and expertise in terms of consulting country-specific features. 

C. In the last 30 years we have successfully completed more than 600 transactions for our clients. This includes global transactions with a transaction value of more than 300 million, but also small and medium-sized transactions in the range of down to 1 million.

Working with a network

of consultants with significant industry experience

Proprietary global database

Access to companies and individuals


designed for specific engagement

no generic templates

Multinational team

that is motivated,
and very efficient


closed 600+ deals


from planning to execution



Of the more than 600 transactions, some stand out, such as the sale of a global cardiovascular brand in the amount of over 600 million,  supporting the sale of a Colombian medium-sized pharmaceutical company to a Spanish listed pharmaceutical company, further, our expertise in the sale of pharmaceutical production facilities. For the latter we were primarily active on behalf of Big Pharma. 

Divestment of
a Colombian
Pharma Company

to a Spanish stock-listed
Pharma Company

Deal Size
25 mn USD

Divestment of a
global Gastro

to a German
Pharma Company

Deal Size
250 mn USD

Divestment of
an European
antibiotic brand

to a Belgian
Pharma Company

Deal Size
40 mn USD

Divestment of a
global cardiovascular

to a German
Pharma Company

Deal Size
200 mn USD

Divestment of
an European

to a German
OTC Company

Deal Size
40 mn USD

Divestment of
a Mexican
Pharma Company

to a LatAm based
Pharma Company

Deal Size
60 mn USD



Within the scope of our consulting services, we can assist companies to fine-tune their strategy and advise them on how to create the basis for an appropriate reorientation with regard to the organization, taking into account the needs of the market and market participants such as patients. 

For this purpose, we have developed the Company Health Generator, which guides our clients systematically and logically through the process of restructuring or reorganization

  1. At first, we analyze the existing corporate strategy, 
  2. then we analyze the existing product portfolio, 
  3. then we analyze the organization and its expertise and capabilities, 
  4. then we work out a gap analysis with the goal of identifying which gaps exist in the portfolio and need to be filled, 
  5. afterwards, we develop a fine tuning of the new corporate strategy, 
  6. afterwards, we help to implement this new strategy in the company organization. 

Finalise Strategy Implementation

The implementation of a new corporate strategy requires a strict approach and procedure. We can accompany this process with the objective that it is completed within a clearly defined time frame. 

  • This includes the preparation of a finance plan, 
  • the preparation of and decision on a divestment plan, including the sale of assets and portfolios and, if applicable, company parts (shares) that are not part of the company’s focus or to sell mature brands.
  • Furthermore, the preparation of an acquisition plan to close gaps in the portfolio by purchasing products for the focus areas of the company (indication focus, geographical priorities, etc.).
  • Finally, based on the overall results and findings, we create an optimization plan to realize the final strategy of the company. 

For all topics it is crucial to determine the responsibilities for the enforcement and implementation of the strategy.

Final Strategy









Allocation of Responsibility for Strategy


Bannert Manlik Consultants

Since 1991, BANNERT MANLIK is one of the leading international strategic consulting firms for the pharmaceutical and healthcare industries.
We assist our clients throughout the entire M&A process, provide portfolio management strategies, as well as support in the realisation of international growth and other strategic goals.


Our Office


Bannert Manlik Consultants GmbH
Maximilianstr. 4e

82319 Starnberg | Germany

Tel: + 49 . 8151. 973 65 0

Special newsletter

To support our clients in considering the effects of the COVID-19 crisis on their business, I will share over the next couple of weeks a number of newsletters on what companies should think about over the next few months to stabilize the company and to build for future success.

These newsletters are issued by Bannert-Manlik Consultants in association with Koru Financial Consulting.


Covid 19 News inside